Use and costs of diagnostic imaging increasing for patients with cancer

April 27, 2010

From 1999 through 2006 the use of diagnostic imaging for Medicare patients with cancer increased, with use of positron emission tomography (PET) increasing the most significantly, according to a study in the April 28 issue of JAMA. Imaging costs for these patients also increased, outpacing the rate of increase in total costs among Medicare beneficiaries with cancer.

Cancer-related expenditures are expected to increase faster than any other area of health care. "Emerging technologies, changing diagnostic and treatment patterns, and changes in Medicare reimbursement are contributing to increasing use of imaging in cancer," the authors write. "The types and costs of imaging, including costly new imaging modalities, among Medicare beneficiaries with cancer have not been examined previously."

Michaela A. Dinan, B.S., of the Duke Clinical Research Institute, Durham, N.C., and colleagues examined changes in the use and costs of imaging and how these changes have influenced the cost of cancer care. The study included an analysis of a nationally representative 5 percent sample of claims from the U.S. Centers for Medicare & Medicaid Services. From 1999 through 2006, there were 100,954 new cases of breast cancer, colorectal cancer, leu¬kemia, lung cancer, non-Hodgkin lymphoma, and prostate cancer.

The researchers found that in each subset of cancer type, the number of positron emission tomography (PET) scans per beneficiary increased at an average annual rate of 35.9 percent to 53.6 percent. "Patients with lung cancer or lymphoma had the largest increase in PET use, accompanied by an overall reduction of conventional nuclear medicine imaging tests in both cancer types and stabilized computed tomography [CT] in the lymphoma group. Increases also occurred in the use of bone density scans (6.3 percent - 20.0 percent), echocardiograms (5.0 percent - 7.8 percent), magnetic resonance imaging (4.4 percent - 11.5 percent), and ultrasound (0.7 percent - 7.4 percent). Use of CT increased in all cancer subgroups (4.5 percent - 7.6 percent) except lymphoma," the authors write.

Use of conventional radiographs decreased or stayed the same in each cancer subgroup but remained the most heavily used imaging modality for all diagnoses, at an average of 4.3 to 12.2 procedures per patient.

The authors also found that for all cancer types, average 2-year imaging costs per beneficiary increased between 5.1 percent and 10.3 percent per year, at least double the rate of increase in overall costs (the cost of cancer care increased 1.8 percent to 4.6 percent per year). Imaging costs for all cancers studied also accounted for a larger percentage of total costs in the 2006 group than in all previous years.

"It is unclear whether the rapid increase in use of advanced imaging is a result of the novelty of the technologies, better outcomes, or a shift to new revenue sources after the enactment of the Medicare Prescription Drug, Improvement, and Modernization Act," the authors write.
-end-
(JAMA. 2010;303[16]:1625-1631. Available pre-embargo to the media at www.jamamedia.org)

Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

The JAMA Network Journals

Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.